Collegium Pharmaceutical Announces $50M Accelerated Share Repurchase

What Happened Collegium Pharmaceutical, Inc. announced on August 12, 2026 (filed on Form 8‑K Aug 13, 2026) that it entered an accelerated share repurchase (ASR) agreement with Jefferies LLC to repurchase $50 million of its common stock. The ASR is part of a previously authorized $150 million share repurchase program approved by the company’s board in July 2025.

Key Details

• Company to pay $50.0 million to Jefferies LLC under the ASR Agreement.
• Initial delivery of 1,556,420 shares based on Collegium’s closing price of $25.70 on Aug 12, 2026 (≈80% of expected total shares under the ASR).
• Final number of shares repurchased will be adjusted based on the volume‑weighted average price (VWAP) during the ASR term; final settlement expected no later than Q4 2026.
• Collegium had approximately 32.5 million shares outstanding as of June 30, 2026.

Why It Matters This transaction reduces the company’s outstanding shares and is a use of corporate cash to return capital to shareholders under the $150M buyback program. The ultimate share count repurchased will depend on market prices (VWAP) during the ASR period, so the final effect on share count and per‑share metrics will be known at settlement. The company’s filing also includes standard forward‑looking statements and notes that outcomes may be affected by market fluctuations and other risks disclosed in its SEC reports.